Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.

Literature DB >> 20038627

In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.

Patricia M Roblin¹, Stephan A Kohlhoff, Charles Parker, Margaret R Hammerschlag.

Abstract

The in vitro activities of CEM-101, telithromycin, azithromycin, clarithromycin, and doxycycline against 10 isolates each of Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae were tested. The MIC at which 90% of the isolates of both C. trachomatis and C. pneumoniae were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by CEM-101 were 0.25 microg/ml (ranges, 0.125 to 0.5 microg/ml for C. trachomatis and 0.25 to 1.0 microg/ml for C. pneumoniae).

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2009 PMID： 20038627 PMCID： PMC2825974 DOI： 10.1128/AAC.01343-09

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

10 in total

1. In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.

Authors: S Strigl; P M Roblin; T Reznik; M R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 2000-04 Impact factor: 5.191

2. The FDA and the case of Ketek.

Authors: David B Ross
Journal: N Engl J Med Date: 2007-04-19 Impact factor: 91.245

3. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.

Authors: Ken B Waites; D M Crabb; Lynn B Duffy
Journal: Antimicrob Agents Chemother Date: 2009-03-02 Impact factor: 5.191

4. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.

Authors: Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens
Journal: Antimicrob Agents Chemother Date: 2009-06-29 Impact factor: 5.191

5. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.

Authors: P M Roblin; M R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 1998-06 Impact factor: 5.191

6. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.

Authors: P M Roblin; M R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 1998-01 Impact factor: 5.191

7. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia.

Authors: P M Roblin; G Montalban; M R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 1994-07 Impact factor: 5.191

8. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.

Authors: S Block; J Hedrick; M R Hammerschlag; G H Cassell; J C Craft
Journal: Pediatr Infect Dis J Date: 1995-06 Impact factor: 2.129

9. Telithromycin use and spontaneous reports of hepatotoxicity.

Authors: David D Dore; Julia R DiBello; Kate L Lapane
Journal: Drug Saf Date: 2007 Impact factor: 5.606

Review 10. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections.

Authors: Margaret R Hammerschlag; Roopali Sharma
Journal: Expert Opin Investig Drugs Date: 2008-03 Impact factor: 6.206

10 in total

21 in total

1. In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K.

Authors: Manuela Donati; Antonietta Di Francesco; Antonietta D'Antuono; Federica Delucca; Alisa Shurdhi; Alessandra Moroni; Raffaella Baldelli; Roberto Cevenini
Journal: Antimicrob Agents Chemother Date: 2010-09-20 Impact factor: 5.191

2. Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment.

Authors: Brian D Jamieson; Sabrina Ciric; Prabhavathi Fernandes
Journal: Antimicrob Agents Chemother Date: 2015-04-13 Impact factor: 5.191

3. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.

Authors: J Gordon Still; Jennifer Schranz; Thorsten P Degenhardt; Drusilla Scott; Prabhavathi Fernandes; Maria J Gutierrez; Kay Clark
Journal: Antimicrob Agents Chemother Date: 2011-01-31 Impact factor: 5.191

Review 4. Atypical Pneumonia: Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia.

Authors: Lokesh Sharma; Ashley Losier; Thomas Tolbert; Charles S Dela Cruz; Chad R Marion
Journal: Clin Chest Med Date: 2016-12-24 Impact factor: 2.878

5. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.

Authors: Jørgen Skov Jensen; Prabhavathi Fernandes; Magnus Unemo
Journal: Antimicrob Agents Chemother Date: 2014-03-17 Impact factor: 5.191

6. Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects.

Authors: Keith A Rodvold; Mark H Gotfried; J Gordon Still; Kay Clark; Prabhavathi Fernandes
Journal: Antimicrob Agents Chemother Date: 2012-07-16 Impact factor: 5.191

7. Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model.

Authors: Olanrewaju O Okusanya; Alan Forrest; Sujata M Bhavnani; Prabhavathi Fernandes; Paul G Ambrose; David R Andes
Journal: Antimicrob Agents Chemother Date: 2019-07-25 Impact factor: 5.191